NCT00354861View on ClinicalTrials.gov

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

February 28, 2006

Conditions
Healthy
Interventions
BIOLOGICAL

hepatitis B antigen (without alum) plus IMP321

hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321

BIOLOGICAL

hepatitis B antigen alone (without alum)

hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline

BIOLOGICAL

Engerix B

20 µg hepatitis B antigen absorbed on alum

Trial Locations (1)

75015

SGS Aster-Cephac, Paris

All Listed Sponsors
collaborator

SGS Aster-Cephac (CRO)

UNKNOWN

lead

Immutep S.A.S.

INDUSTRY

NCT00354861 - A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321 | Biotech Hunter | Biotech Hunter